Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
J Psychiatr Res. 2024 Feb;170:19-26. doi: 10.1016/j.jpsychires.2023.11.037. Epub 2023 Dec 3.
ADHD is often described as a disorder of altered reward sensitivity, yet few studies have examined the extent to which: (i) treatments for ADHD impact reward-related mechanisms; and (ii) changes in the reward system are associated with clinical improvement. This study addresses these issues - examining the extent to which clinical improvement following lisdexamfetamine (LDX) treatment is associated with changes in brain reward system activation.
Twenty adults (M = 11, 55%, F = 9, 45%), ages 19-52 (M = 33.9, SD = 10.0) with ADHD participated in a randomized cross-over study with lisdexamfetamine (LDX) and placebo (PB). Changes in brain activation were assessed during functional magnetic resonance (fMRI) scans: after receiving 3-5 weeks of treatment with LDX and 3-5 weeks of no drug/PB. fMRI contrasts were derived from the passive-avoidance (PA) learning task, which assessed reward-related learning using computational variables. We analyzed the following conditions: the Choice-Phase, modulated by the expected value (EV; i.e., object-choose and object-reject), and the Feedback-Phase, modulated by the prediction error (PE; i.e., reward and punish). Clinical symptom severity was assessed via interview with the ADHD-Rating Scale (ADHD-RS-IV). To address the primary objective, we performed group-level mass-univariate regression analyses between LDX and PB of percent change of the ADHD-RS total scores and the four contrast images under the Choice- and Feedback-conditions. Significance was set at a whole-brain voxel-wise threshold of p < 0.05 with family-wise error (FWE) correction and an extent (cluster) threshold of 50 contiguous voxels.
Improvement in ADHD symptoms with LDX was accompanied by significantly increased activation in a series of brain regions previously implicated in reinforcement processing in the choice and feedback conditions (e.g., left caudate and putamen, right orbitofrontal cortex, left middle frontal, superior frontal, and precentral gyri).
These findings, while preliminary, are the first to show that ADHD symptom improvement with stimulant treatment is associated with increased responsiveness of brain systems engaged in reward processing. Results support the hypothesis that LDX treatment may restore balance to dysfunction (e.g., hypoactivation) within the brain reward circuitry in adults with ADHD. Trial RegistrationClinicaltrials.gov Identifier: NCT01924429.
注意力缺陷多动障碍(ADHD)常被描述为一种奖赏敏感性改变的障碍,但很少有研究检查以下方面的情况:(i)ADHD 的治疗方法是否会影响与奖赏相关的机制;(ii)奖赏系统的变化是否与临床改善有关。本研究解决了这些问题——检查接受 lisdexamfetamine(LDX)治疗后的临床改善与大脑奖赏系统激活的变化之间的关联程度。
20 名年龄在 19 至 52 岁(M=33.9,SD=10.0)的 ADHD 成年患者(M=11,55%,F=9,45%)参与了一项 lisdexamfetamine(LDX)和安慰剂(PB)的随机交叉研究。在功能磁共振(fMRI)扫描期间评估大脑激活的变化:在接受 3-5 周的 LDX 治疗和 3-5 周的无药物/PB 治疗后。fMRI 对比源自被动回避(PA)学习任务,该任务使用计算变量评估与奖赏相关的学习。我们分析了以下条件:选择阶段,由预期值(EV;即,物体选择和物体拒绝)调制;反馈阶段,由预测误差(PE;即,奖赏和惩罚)调制。临床症状严重程度通过 ADHD-Rating Scale(ADHD-RS-IV)访谈进行评估。为了解决主要目标,我们在 LDX 和 PB 之间进行了组水平的多元回归分析,分析 ADHD-RS 总分和选择和反馈条件下的四个对比图像的百分比变化。采用全脑体素水平的 p < 0.05 的阈值(具有家族错误(FWE)校正和 50 个连续体素的簇阈值)来确定显著性。
ADHD 症状的改善与一系列大脑区域的激活增加有关,这些区域先前涉及强化处理的选择和反馈条件(例如,左侧尾状核和壳核、右侧眶额皮质、左侧中额、额上和中央前回)。
这些发现虽然初步,但却是首次表明 ADHD 症状改善与兴奋剂治疗相关,这与奖赏加工大脑系统的反应性增加有关。结果支持以下假设:即 LDX 治疗可能会恢复 ADHD 患者大脑奖赏回路中功能障碍(例如,低激活)的平衡。
Clinicaltrials.gov 标识符:NCT01924429。